Wavelength-Pharmaceuticals-Insert
X

Find Clinical Drug Pipeline Developments & Deals by Arena Pharmaceuticals

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
Therapeutic Area filter
    Study Phase filter
      Country filter
        News Type filter
          Company filter
            refresh

            Companies By Therapeutic Area Full Screen

            Development Status Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Etrasimod

            Therapeutic Area: Gastroenterology Product Name: Undisclosed

            Highest Development Status: Phase III Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable April 01, 2020

            Details:

            Positive topline data from Phase 1 study demonstrated significant reduction in heart rate effect, particularly during the initial 4-hour monitoring period.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): APD418

            Therapeutic Area: Cardiology/Vascular Diseases Product Name: Undisclosed

            Highest Development Status: Phase I Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable January 16, 2020

            Details:

            APD418 currently in Phase 1 clinical investigation - data expected this year.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Etrasimod

            Therapeutic Area: Gastroenterology Product Name: Undisclosed

            Highest Development Status: Phase III Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable January 06, 2020

            Details:

            Arena Pharmaceuticals expanded multi-program collaboration with Beacon Discovery for immune and inflammatory targets (Project Cabrillo).